NIKKEI 225
38,229.11 +155.13 (+0.41%) HANG SENG
18,918.31 +380.50 (+2.05%) CRUDE OIL
79.86 +0.60 (+0.76%) GOLD FUTURES
2,367.40 +27.10 (+1.16%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,139.53 +909.37 (+1.85%)
Immunocore Holdings plc (IMCR)
After hours:
- GuruFocus.com
Immunocore Holdings PLC Reports Q1 2024 Earnings: Misses EPS Estimates, Surpasses Revenue Forecasts
Comprehensive Analysis of Immunocore's Financial Performance and Strategic Updates
- GlobeNewswire
Immunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMC
- Globe Newswire
Immunocore announces upcoming presentation and posters at ASCO 2024
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 24 April 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to ra
